© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
April 01, 2021
Isatuximab in combination with carfilzomib and dexamethasone reduced the risk of disease progression or death by 45% versus standard of care alone.
March 29, 2021
In a clinical trial of idecabtagene vicleucel in multiple myeloma, the overall response rate for the efficacy evaluable population was 72%, and 28% of participants achieved a stringent complete response.
March 12, 2021
Bristol Myers Squibb and bluebird bio are seeking FDA approval for ide-cel as a standard therapy for relapsed myeloma, with a decision expected by the end of March.
March 09, 2021
Teclistamab showed promising clinical activity and a tolerable safety profile in patients with relapsed/refractory multiple myeloma.
March 01, 2021
The FDA has approved melphalan flufenamide (Pepaxto; melflufen) for use in combination with dexamethasone to treat adult patients with relapsed or refractory multiple myeloma.
January 14, 2021
The FDA has granted an orphan drug designation to the BCMA-targeted trispecific T-cell activating recombinant protein construct as treatment for patients with multiple myeloma.
December 21, 2020
Three monoclonal antibodies, 1 antibody-drug conjugate, and 1 nuclear export inhibitor have been approved by the FDA for relapsed/refractory (R/R) multiple myeloma in the past 4 years.
December 19, 2020
Selinexor (Xpovio; Karyopharm Therapeutics Inc.) in combination with bortezomib (Velcade; Takeda) and dexamethasone was approved for the treatment of adult patients with multiple myeloma who have received at least 1 prior therapy.
December 16, 2020
CAR T-cell therapy associated with greater anti-cancer activity in treating multiple myeloma.
December 11, 2020
For patients with relapsed/refractory multiple myeloma (RRMM), teclistamab was found to have a manageable safety profile, according to data presented at the virtual American Society of Hematology conference.